<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00481780</url>
  </required_header>
  <id_info>
    <org_study_id>2004</org_study_id>
    <nct_id>NCT00481780</nct_id>
  </id_info>
  <brief_title>PTA vs. CB-PTA for Treatment of Femoropopliteal Artery In-Stent Restenosis</brief_title>
  <official_title>Conventional Balloon Angioplasty vs. Cutting Balloon Angioplasty for Treatment of Femoropopliteal Artery In-Stent Restenosis - A Randomized Controlled Pilot Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vienna General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vienna General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Percutaneous transluminal angioplasty (PTA) is a minimally invasive technique for treatment&#xD;
      of superficial femoropopliteal artery (SFA) obstructions or occlusions in patients with&#xD;
      intermittent claudication as well as critical limb ischemia. Initial technical success rates&#xD;
      of above 95% can be achieved and acceptably low rates of complications are consistently&#xD;
      reported in the literature. There is a direct relation between treated vessel length and&#xD;
      patency rates. One year patency of lesions longer than 10cm has only been 22% at one-year&#xD;
      follow up. This major drawback limits a widespread applicability of PTA, and the indication&#xD;
      of PTA particularly in patients with intermittent claudication is discussed&#xD;
      controversially.With the introduction of endovascular stents, the problems of elastic recoil&#xD;
      and residual stenoses due to arterial dissection could be resolved and initial reports of&#xD;
      stenting for the treatment of occlusive atherosclerotic disease of the SFA showed promising&#xD;
      results with primary and secondary patency rates of 87% to 90% after 18 months. However,&#xD;
      subsequent studies demonstrated that exaggerated neo-intimal hyperplasia in the stented&#xD;
      segment frequently leads to instent restenosis. This condition will be of greater importance&#xD;
      with increasing number of stent implantation procedures during the last years. The concept of&#xD;
      cutting balloon seems appealing for this indication, as the balloon-mounted microtomes&#xD;
      guarantee smooth lumen gain within the stent, without the risk of vessel wall perforation.&#xD;
      Initial reports of the use of the cutting balloon for the treatment of occlusive&#xD;
      atherosclerotic disease of the SFA show promising results, indicating that the problems of&#xD;
      elastic recoil and residual stenoses due to arterial dissection might be resolved. The&#xD;
      cutting balloon has four tiny microtomes (&lt; 0.1mm height) on the outside, which cut the&#xD;
      fibrous plaque during expansion of the balloon. Consequently the problem of elastic recoil is&#xD;
      ideally addressed, additionally less trauma is exercised on the vessel wall during dilatation&#xD;
      of the balloon. This might be achieved by a reduction of vessel wall trauma, vessel wall&#xD;
      inflammation and consequently reduced neointimal formation. Although the indications for&#xD;
      CB-PTA in the SFA includes significant residual stenosis or in-stent restenosis, there are&#xD;
      currently no published randomized controlled trials (RCT) comparing PTA vs. cutting balloon&#xD;
      angioplasty (CB-PTA) for any specific condition. This lack of data led us to initiate a RCT&#xD;
      comparing primary PTA vs. CB-PTA for treatment of in-stent restenoses in patients with&#xD;
      intermittent claudication or critical limb ischemia with TASC category A-B in the&#xD;
      femoropopliteal artery .&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Percutaneous transluminal angioplasty (PTA) is a minimally invasive technique for treatment&#xD;
      of superficial femoropopliteal artery (SFA) obstructions or occlusions in patients with&#xD;
      intermittent claudication as well as critical limb ischemia. Initial technical success rates&#xD;
      of above 95% can be achieved and acceptably low rates of complications are consistently&#xD;
      reported in the literature. There is a direct relation between treated vessel length and&#xD;
      patency rates. One year patency of lesions longer than 10cm has only been 22% at one-year&#xD;
      follow up. This major drawback limits a widespread applicability of PTA, and the indication&#xD;
      of PTA particularly in patients with intermittent claudication is discussed controversially.&#xD;
&#xD;
      With the introduction of endovascular stents, the problems of elastic recoil and residual&#xD;
      stenoses due to arterial dissection could be resolved and initial reports of stenting for the&#xD;
      treatment of occlusive atherosclerotic disease of the SFA showed promising results with&#xD;
      primary and secondary patency rates of 87% to 90% after 18 months. However, subsequent&#xD;
      studies demonstrated that exaggerated neo-intimal hyperplasia in the stented segment&#xD;
      frequently leads to instent restenosis. This condition will be of greater importance with&#xD;
      increasing number of stent implantation procedures during the last years. Repeated PTA of&#xD;
      instent restenosis is performed for revascularisation in these patients, but the gold&#xD;
      standard for treatment of instent restenosis is unknown and the rate of recurrence after&#xD;
      repeat treatment of instent restenosis remains high. The concept of cutting balloon seems&#xD;
      appealing for this indication, as the balloon-mounted microtomes guarantee smooth lumen gain&#xD;
      within the stent, without the risk of vessel wall perforation (due to the protecting effect&#xD;
      of the stent as the outer limit for the microtomes).&#xD;
&#xD;
      Initial reports of the use of the cutting balloon for the treatment of occlusive&#xD;
      atherosclerotic disease of the SFA show promising results, indicating that the problems of&#xD;
      elastic recoil and residual stenoses due to arterial dissection might be resolved. The&#xD;
      cutting balloon has four tiny microtomes (&lt; 0.1mm height) on the outside, which cut the&#xD;
      fibrous plaque during expansion of the balloon. Consequently the problem of elastic recoil is&#xD;
      ideally addressed, additionally less trauma is exercised on the vessel wall during dilatation&#xD;
      of the balloon. This might be achieved by a reduction of vessel wall trauma, vessel wall&#xD;
      inflammation and consequently reduced neointimal formation. The cutting balloon can be used&#xD;
      for pre-dilatation with diameters slightly less than the target vessel diameter, but still&#xD;
      cuts the fibrous plaque, the desired target vessel diameter is then achieved by final touch&#xD;
      up dilatation with a standard angioplasty balloon. In the coronary arteries the cutting&#xD;
      balloon has been used in randomized studies comparing CB-PTCA to PTCA, as well as in trials&#xD;
      for the treatment of in-stent restenosis. All of these trials demonstrated the safety and&#xD;
      efficacy of the cutting balloon, only larger randomized trials failed to proof superiority to&#xD;
      conventional PTCA. Data in the peripheral arteries are at least scarce. Although the&#xD;
      indications for CB-PTA in the SFA includes significant residual stenosis or in-stent&#xD;
      restenosis, there are currently no published randomized controlled trials (RCT) comparing PTA&#xD;
      vs. cutting balloon angioplasty (CB-PTA) for any specific condition. This lack of data led us&#xD;
      to initiate a RCT comparing primary PTA vs. CB-PTA for treatment of in-stent restenoses in&#xD;
      patients with intermittent claudication or critical limb ischemia with TASC category A-B in&#xD;
      the femoropopliteal artery . The primary endpoint is the occurrence of restenosis as an&#xD;
      ultrasonographic reduction of the vessel lumen diameter &gt;50% within 6 months after&#xD;
      endovascular treatment. In addition, the course of postintervention inflammation as indicated&#xD;
      by serum levels of C-reactive protein (CRP), serum amyloid A (SAA) and fibrinogen will be&#xD;
      assessed.&#xD;
&#xD;
      STUDY DESIGN, INCLUSION AND EXCLUSION CRITERIA. Patients with in-stent restenosis&#xD;
      (ultrasonographic stenosis &gt; 50% of the vessel lumen diameter) after prior PTA and Stent&#xD;
      placement of the SFA will be enrolled to this single-center prospective RCT. The protocol has&#xD;
      to be approved by the institutional ethics committee and all patients have to provide written&#xD;
      informed consent before enrollment. Entry criteria include symptomatic peripheral artery&#xD;
      disease with intermittent claudication (Fontaine stage IIa or b), or critical limb ischemia&#xD;
      related to a recurrent stenosis in a previously stented segment of up to 20 cm length.&#xD;
      Exclusion criteria history of intolerance of anti-platelet therapy, or adverse reaction to&#xD;
      heparin, bleeding diathesis, creatinine &gt;2.5 mg/dL, hemodialysis, active bacterial infection,&#xD;
      and allergy to contrast media, pregnancy and disability to give informed consent.&#xD;
&#xD;
      FOLLOW-UP. ABI testing, treadmill exercise, and Duplex-sonography of the treated vessels will&#xD;
      be performed in all patients at 1, 3, and 6 months after treatment. A peak systolic velocity&#xD;
      of â‰¥ 2.4 was considered indicative of a &gt;50% narrowing and was defined as indicative of a&#xD;
      restenosis10. Reintervention or surgical bypass at the treated segment are also defined as a&#xD;
      restenosis and loss of primary patency. An improvement of at least one Fontaine category&#xD;
      above baseline is used to define clinical success in association with maintenance of at least&#xD;
      a 0.15 increase in exercise ABI from the preprocedure level.&#xD;
&#xD;
      COMPLICATIONS are classified as either major or minor (as described in Appendix A). Major&#xD;
      complications are e.g. bleedings at the puncture side with hematoma and a decrease of serum&#xD;
      hemoglobin more than 2 g/dl, loss of stent in the artery , vessel rupture, amputation,&#xD;
      macroembolisation with need for further revascularisation and life threatening bleeding&#xD;
      complications.&#xD;
&#xD;
      STUDY ENDPOINTS. The primary study endpoint is the occurrence of a &gt;50% restenosis at the&#xD;
      treated segment at 6 months post-intervention as determined by duplex ultrasound (in-segment&#xD;
      restenosis). Secondary objectives are primary technical success rates (residual stenosis &lt;30%&#xD;
      without need for secondary stent implantation, primary assisted and secondary patency,&#xD;
      clinical patency, target vessel and target lesion revascularization, and cardiovascular&#xD;
      adverse events at 1, 3, and 6 months after the procedure. Furthermore, the course of&#xD;
      inflammatory parameters will be assessed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2004</start_date>
  <completion_date>April 2007</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary study endpoint is the occurrence of a &gt;50% restenosis at the treated segment at 6 months postintervention as determined by duplex ultrasound (in-segment restenosis)</measure>
    <time_frame>within 6 months follow up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>primary technical success rates residual stenosis &lt;30% without need for secondary stent implantation, primary assisted and secondary patency, clinical patency, target vessel and target lesion revascularization, cardiovascular adverse events</measure>
    <time_frame>within 6 months follow up</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">40</enrollment>
  <condition>Instent Restenosis</condition>
  <condition>Cutting Balloon Angioplasty</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>plain balloon angioplasty</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>cutting balloon angioplasty</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients with in-stent restenosis (ultrasonographic stenosis &gt; 50% of the vessel lumen&#xD;
             diameter) after prior PTA and Stent placement of the SFA&#xD;
&#xD;
          -  symptomatic peripheral artery disease with intermittent claudication or critical limb&#xD;
             ischemia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  history of intolerance of anti-platelet therapy&#xD;
&#xD;
          -  adverse reaction to heparin&#xD;
&#xD;
          -  bleeding diathesis&#xD;
&#xD;
          -  creatinine &gt;2.5 mg/dL&#xD;
&#xD;
          -  hemodialysis&#xD;
&#xD;
          -  active bacterial infection&#xD;
&#xD;
          -  allergy to contrast media&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  disability to give informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Minar Erich, Prof.Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>General Hospital of Vienna</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>General Hospital of Vienna</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>May 2007</verification_date>
  <study_first_submitted>June 1, 2007</study_first_submitted>
  <study_first_submitted_qc>June 1, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2007</study_first_posted>
  <last_update_submitted>September 10, 2007</last_update_submitted>
  <last_update_submitted_qc>September 10, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 11, 2007</last_update_posted>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

